MEKanistic Therapeutics Reports Preclinical Results of MTX-531 for Cancer Treatment
Shots:
- MEKanistic reported the publication of preclinical results of MTX-531 (EGFR & PI3K inhibitor) for cancer treatment in Nature Cancer
- Results showed that MTX-531 has nanomolar potency against EGFR (14.7nM) and PI3K (6.44nM) with high selectivity without causing hyperglycemia in mice
- MTX-531 also showed tumor regression in HNSCC models, effectively inhibiting PI3K and EGFR signaling, achieved complete tumor regressions and improved survival by 62% to >500% & doubled tumor regressions (100% ORR) combine with trametinib & sotorasib in multiple KRAS mutant colorectal and pancreatic tumor models
Ref: MEKanistic Therapeutics | Image: MEKanistic Therapeutics
Related News:- Hinova Pharmaceuticals’ HP518 Gains the US FDA’s Fast Track Designation to Treat Triple-Negative Breast Cancer (TNBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
